摘要
目的:从治疗非酒精性脂肪肝临床有效复方"祛湿化瘀方"已知的中药组分或成分中筛选防治脂肪肝的中药组分或成分复方,并运用相同动物模型验证其对实验性脂肪肝的疗效。方法:以"祛湿化瘀方"中5种已被认知的、能被分离提取或购买的有效组分或单体(绿原酸、栀子苷、姜黄素、虎杖苷、白术多糖)为研究对象,运用高脂饮食8周诱导大鼠脂肪肝模型,采用均匀设计"5因子10水平"分组设计。给药4周,以肝组织三酰甘油(TG)含量为筛选指标,并经均匀设计回归分析获得"中药组分或成分复方"。再次运用高脂饮食诱导的实验性脂肪肝动物模型,以祛湿化瘀方及西药罗格列酮为对照,通过检测实验大鼠肝组织TG、血清谷丙转氨酶(ALT)以及肝组织HE染色脂肪变性程度,对所得中药成分复方的抗脂肪肝疗效进行验证与对照。结果:①筛选试验获得回归方程为Y=71.966-19.798X4+18.687X1X4,提示栀子苷(X4)、绿原酸(X1)组合(命名为"ZL方")对肝组织TG抑制作用最佳;②验证实验结果显示,"ZL方"可显著降低高脂饮食诱导的脂肪肝模型大鼠肝组织TG含量,降低血清ALT活性(P<0.01)。结论:运用均匀设计筛选获得的ZL方对高脂饮食诱导的大鼠肝脏脂肪沉积及肝损伤具有显著的防治作用。
Objective： To selectee the ingredients or components in “ Qushi Huayu Formula ” for the treatment of non-alcoholic fatty liver disease （ NAFLD） and to verify its curative effect by animal model. Methods ： The 5 kind of ingredients or components in “ Qushi Huayu Formula” were used to be the subjects. The rat models were established by high-fat diet for 8 weeks. The models were divided by uniform design and administered with medicine for 4 weeks. The TG in hepatic tissue was used to be the screen index. Then the fatty liver models were induced by high fat diet. The western medicine Rosiglitazone was the control group. The TG, ALT and fatty degeneration were detected. The therapeutic effect was tested and verified. Results ：① Combination of Geniposide and Chlorogenic acid has inhibition effect on TG ;② ZL Prescription reduced the content of TG and ALT activity （P 〈0. Ol）. Conclusion： ZL prescription has positive effect on preventing and treating fat deposition and liver damage.
出处
《上海中医药大学学报》
CAS
2013年第4期53-57,共5页
Academic Journal of Shanghai University of Traditional Chinese Medicine
基金
国家自然科学基金资助项目(81173404)
上海市教委创新团队项目(第1期)
国家中医药管理局中医肝胆病重点学科项目(2010sh)
关键词
有效组分复方
脂肪肝
祛湿化瘀方
均匀设计
Active composition of Chinese medicine ； fatty liver； “ Qushi Huayu Formula”； uniform design
